Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRA | P11474 | 12/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | ESRRB | O95718 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | ESRRG | P62508 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.42 |
| ▸ | IGF1R | P08069 | 1/20 | 0.42 |
| ▸ | FOXM1 | Q08050 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3762233 | 1.00 | ESRRA (0.50) | ESRRAHPGDCYP3A4ESRRBESR1 | |
| SCHEMBL12997360 | 0.93 | PDE4B (0.46) | ESRRAHPGDPIM1PIM2 | |
| SCHEMBL3761605 | 0.90 | HPGD (0.50) | ESRRAHPGDCYP3A4ESRRBESR1 | |
| SCHEMBL3761607 | 0.90 | HPGD (0.50) | ESRRAHPGDCYP3A4ESRRBESR1 | |
| SCHEMBL3762303 | 0.90 | ESRRA (0.45) | ESRRAHPGDPTPN1PIM1PIM2 | |
| SCHEMBL3762308 | 0.90 | ESRRA (0.45) | ESRRAHPGDPTPN1PIM1PIM2 | |
| SCHEMBL3763212 | 0.88 | ESRRA (0.58) | ESRRAHPGDCYP3A4PIM1PIM2 | |
| SCHEMBL3761628 | 0.88 | HPGD (0.51) | ESRRAHPGD | |
| SCHEMBL3761632 | 0.88 | HPGD (0.51) | ESRRAHPGD | |
| SCHEMBL3763210 | 0.88 | ESRRA (0.58) | ESRRAHPGDCYP3A4PIM1PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305174-A1 | Novel Heterocyclic Derivatives | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2010-12-02 | — | — | US | claimed |
| US-20100305174-A1 | Novel Heterocyclic Derivatives | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2010-12-02 | — | — | US | disclosed |
| US-20100305174-A1 | Novel Heterocyclic Derivatives | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2010-12-02 | — | — | US | disclosed |
| EP-1868990-A2 | NOVEL HETEROCYCLIC DERIVATIVES | Orchid Research Laboratories Limited (IN) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006109146-A2 | NOVEL HETEROCYCLIC DERIVATIVES | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305174-A1 | Novel Heterocyclic Derivatives | UGT1A1, CYP3A4, CYP3A43 | ESRRA 3987/4885HPGD 228/4885CYP3A4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.